Market Overview

Goldman Sachs Says MannKind Has 55% Downside

Goldman Sachs Says MannKind Has 55% Downside
Related MNKD
22 Biggest Mid-Day Losers For Thursday
Mid-Morning Market Update: Markets Open Lower; Macy's Profit Misses Expectations

Goldman Sachs downgraded MannKind Corporation (NASDAQ: MNKD) to a Sell from Neutral, noting that the risk/reward ratio from selling the stock is 55 percent to the downside versus just 5 percent to the upside. The analysts placed a price target of $3 on the shares, which closed Monday at $6.64.

The stock was recently down 11 percent at $5.88.

Goldman Sachs said that the biotech company's diabetes product's launch will be slower than expected with the firm also experiencing "more difficult pricing." Therefore, the analysts pegged 2019-2021 EPS at a 30 percent discount to consensus estimates, leading them to the $3 price target.

Related Link: MannKind's Short Interest Has 'Grown High,' Analyst Says

Most concerning, the analysts said, was MannKind's launch of Afrezza, which has "fallen short of our expectations." The analysts halved Afrezza's sales targets to $1 billion in 2025. Simultaneously, other recent diabetes products have fallen 75 percent short of Goldman Sachs estimates, leading the firm to conclude that Afrezza's initial hiccups are not temporary.

Image credit: VladLazarenko, Wikimedia

Latest Ratings for MNKD

Nov 2015Griffin SecuritiesDowngradesBuyNeutral
Nov 2015RBC CapitalDowngradesOutperformUnderperform
Sep 2015PiperJaffrayDowngradesNeutralUnderweight

View More Analyst Ratings for MNKD
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Biotech Downgrades Price Target Analyst Ratings General Best of Benzinga


Related Articles (MNKD)

View Comments and Join the Discussion!